Merck Knocks Out Second Fosamax Test Case Before Trial
Wyeth and its new parent Pfizer are probably wishing they had more to be thankful for this week, after being hit with jury awards totaling more than $100 million over hormone drugs. But what started out as a tough week for Big Pharma got a little better late Monday, when Manhattan federal Judge John Keenan dismissed the second of three bellwether cases facing Merck over its osteoporosis drug Fosamax just weeks before it was set for trial.
By David Bario|November 25, 2009 at 12:00 AM
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
Wyeth and its new parent Pfizer are probably wishing they had more to be thankful for this week, after being hit with jury awards totaling $103 million over hormone drugs. But what started out as a tough week for Big Pharma got a little better late Monday, when Manhattan federal District Court Judge John Keenan dismissed the second of three bellwether cases facing Merck over its osteoporosis drug Fosamax just weeks before it was set for trial. Keenan ruled on Monday that the plaintiff in the second test case, a 74-year-old Mississippian named Bessie Flemings, had failed to present admissible evidence of specific causation tying her jaw problems to Fosamax. The case had been set to go to trial in January. We’re neither doctors nor lawyers, but it strikes us that Flemings’ situation is pretty extreme for a test plaintiff. The opinion stated that, along with osteoporosis, Flemings “has a history of serious medical problems” including congestive heart failure, vascular disease and skin cancer. She has smoked cigarettes since age eight, and continues to smoke despite suffering from chronic obstructive pulmonary disease and being dependent on an oxygen tank to breathe. But it wasn’t Flemings’ abominable health that finally scuttled her Fosamax claims. Keenan wrote that neither of the dentists who treated her injury and were offered as experts was able to credibly link Flemings’ jaw damage to her use of Fosamax. One of the doctors had no real opinion at all on a possible link, while the other’s opinion was based only on “subjective belief,” the judge wrote. Merck’s lead lawyer, Venable‘s Paul Stain, was has not available to comment directly, but he issued the following statement through Merck: “We are pleased that the Court agreed with us that Ms. Flemings did not present any reliable evidence supporting her claim that FOSAMAX caused her to suffer ONJ [osteonecrosis of the jaw] … . Unfortunately, Ms. Flemings had medical problems that cause people to develop jaw problems regardless of whether they were taking FOSAMAX.” Merck was also represented by Norman Kleinberg and Theodore Mayer of Hughes Hubbard & Reed in the case. Flemings’ lawyer, Robert Germany of Pittman, Germany, Roberts & Welsh, did not respond to our request for comment. The Fosamax plaintiffs all claim that their use of the drug for osteoporosis resulted in painful damage to bone in their jaws and that Merck failed to adequately warn about possible complications. Nearly 900 Fosamax cases are consolidated before Keenan, who last September declared a mistrial in the first test case. That case is set to be re-tried in the spring. Trial in the third case is scheduled for April 19. Daniel Osborn of Osborn Law, who represents the plaintiff in that case, was not available for comment on Tuesday.
This content has been archived. It is available exclusively through our partner LexisNexis®.
To view this content, please continue to Lexis Advance®.
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
With this subscription you will receive unlimited access to high quality, online, on-demand premium content from well-respected faculty in the legal industry. This is perfect for attorneys licensed in multiple jurisdictions or for attorneys that have fulfilled their CLE requirement but need to access resourceful information for their practice areas.
Our Team Account subscription service is for legal teams of four or more attorneys. Each attorney is granted unlimited access to high quality, on-demand premium content from well-respected faculty in the legal industry along with administrative access to easily manage CLE for the entire team.
Gain access to some of the most knowledgeable and experienced attorneys with our 2 bundle options! Our Compliance bundles are curated by CLE Counselors and include current legal topics and challenges within the industry. Our second option allows you to build your bundle and strategically select the content that pertains to your needs. Both options are priced the same.
Dynamically explore and compare data on law firms, companies, individual lawyers, and industry trends.
Exclusive Depth and Reach.
Legal Compass includes access to our exclusive industry reports, combining the unmatched expertise of our analyst team with ALM’s deep bench of proprietary information to provide insights that can’t be found anywhere else.
Big Pictures and Fine Details
Legal Compass delivers you the full scope of information, from the rankings of the Am Law 200 and NLJ 500 to intricate details and comparisons of firms’ financials, staffing, clients, news and events.
Webcast Date: Wednesday, July 22, 2020 | According to a recent Gallup study, 62% of U.S. employees worked from home this past April, reflecting a global migration to remote environments as the COVID-19 pandemic spread.
Webcast Date: Wednesday, July 22, 2020 | Privacy remains one of the top issues for in-house counsel and law firms, and those issues underscoring the need for data privacy have become even more pronounced with the onset of the global COVID-19 pandemic.
As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters.
Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss.
Tailored just for you. In your inbox. Every day.